Lisa Takagi on Muck Rack

Lisa Takagi

Verified
Japan
As seen in: Scrip, The Pink Sheet, IT Media, Citeline, Generics Bulletin, HBW Insight, In Vivo, The Signal Halifax
Managing Editor, Japan for @PharmaScrip and @PharmaPinkSheet . All views are my own. 製薬業界向け英字媒体Scrip、Pink Sheetの日本担当マネージングエディター。時々日本語で投稿します
Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work. Claim your profile

Get in touch with Lisa

Contact Lisa, search articles and posts on X, monitor coverage, and track replies from one place.

Learn more about Muck Rack

Actions

Share this page

Is this you?

As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile

Articles

Japan Awards Global-First Reimbursement To Ishin’s Allostem, Heihe’s Risovalisib

|
By Lisa Takagi Verified
| The Pink Sheet Verified
Japan sets reimbursement prices for four new therapies, including two which recently received global-first approvals in the country. Japan’s Ministry of Health, Labour and Welfare (MHLW) has granted reimbursement prices to four newly approved products under its national health insurance (NHI) scheme, including to Ishin Pharma’s autologous cell therapy Allostem (nivadstrocel), which recently earned a global-first approval in the country for epidermolysis bullosa.
Open in Who Shared Issue with article?

Tanabe Divests Plants To Towa, Focuses On R&D And Japan Market

|
By Lisa Takagi Verified
| Scrip Verified
Tanabe transfers its Japan manufacturing subsidiary and 17 products to Towa to concentrate resources on Japan-centric R&D and business development across CNS, oncology, immune and rare disease categories.
Open in Who Shared Issue with article?

KM Biologics Balances Domestic Hemophilia Demand With Export Ambitions

|
By Lisa Takagi Verified
| Scrip Verified
KM Biologics is pursuing Japanese export approval for its hemophilia product Byclot while needing to meet requirements for uninterrupted domestic supplies, in line with Japan's self-sufficiency priorities. While still promising to meet Japanese government requirements to prioritize supply to the domestic market, KM Biologics is aiming to secure official approval to export its hemophilia treatment to more global markets amid growing international demand.
Open in Who Shared Issue with article?
See all 502 articles
 •  Privacy  •  Terms  •  Security and Legal  •   •   •   • 

© 2026 Muck Rack

SOC 2® Certified